The management of newly diagnosed and relapsed acute lymphocytic leukemia (ALL) has traditionally relied on combination chemotherapy, but novel immune-based approaches are rapidly changing the treatment landscape. This education session will focus on the role of antibody therapy for ALL and discuss the experience with chimeric antigen receptor (CAR) T cells. Further, this session will address critical challenges associated with the use of these novel therapies including toxicity and cost.
Dr. Michaela Liedtke will discuss monoclonal and bi-specific antibodies including rituximab, inotuzumab ozogamicin and blinatumomab. She will highlight key differences in their mechanism of action and provide an overview of clinical trial results that support their use. Dr. Liedtke will summarize current recommendations and review ongoing clinical studies using antibody-based ALL therapy.
Dr. Michael Pulsipher will review the role of CAR T-cell therapy in ALL and compare this approach with hematopoietic stem cell transplant. CAR T-cell therapy is still early in its development, and Dr. Pulsipher will describe how different CAR T-cell constructs can be used safely and optimally. He will then summarize practical issues associated with successfully getting patients to this therapy, and project how CAR T cells fit into our treatment paradigms now and going forward.
Dr. Mark Litzow will review some of the major toxicities that have arisen in the setting of the new immunotherapies that are revolutionizing the treatment of ALL. He will discuss how these toxicities need to be accounted for as clinicians plan the overall management of their patients. The financial burden of these new immunotherapies will be discussed and placed in the context of the benefits these therapies bring to patients.